RT Journal Article
SR Electronic
T1 Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.06.21254949
DO 10.1101/2021.04.06.21254949
A1 Agha, Mounzer
A1 Blake, Maggie
A1 Chilleo, Charles
A1 Wells, Alan
A1 Haidar, Ghady
YR 2021
UL http://medrxiv.org/content/early/2021/04/07/2021.04.06.21254949.abstract
AB Studies describing SARS-CoV-2 immune responses following mRNA vaccination in hematology malignancy (HM) patients are virtually non-existent. We measured SARS-CoV-2 IgG production in 67 HM patients who received 2 mRNA vaccine doses. We found that 46% of HM patients did not produce antibodies and were therefore vaccine non-responders. Patients with B-cell CLL were at a particularly high risk, as only 23% had detectable antibodies despite the fact that nearly 70% of these patients were not undergoing cancer therapy. HM patients should be counseled about the ongoing risk of COVID-19 despite vaccination. Routine measurement of post-vaccine antibodies in HM patients should be considered. Novel strategies are needed to prevent COVID-19 in these individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number K23AI154546 awarded to G.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. None of the author received received payment or services from a third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by the University of Pittsburgh IRB (STUDY21030056)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are will the first and senior authors and are available upon request.